GeneFerm Biotechnology Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jinde Jin

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Geschäftsführer

Jinde Jin

no data

GeneFerm Biotechnology Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021

Recent updates

New minor risk - Profit margin trend

Upcoming dividend of NT$2.00 per share

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: NT$0.20 loss per share (vs NT$0.73 profit in 1Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Full year 2023 earnings released: EPS: NT$3.01 (vs NT$2.26 in FY 2022)

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: NT$1.13 (vs NT$0.72 in 2Q 2022)

Upcoming dividend of NT$1.50 per share at 1.4% yield

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$2.26 (vs NT$1.45 in FY 2021)

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.61 (vs NT$0.45 in 3Q 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings released: EPS: NT$0.50 (vs NT$0.31 in 1Q 2021)

Third quarter 2021 earnings released: EPS NT$0.45 (vs NT$0.15 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$0.083 per share

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.20 loss in 1Q 2020)

GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)

Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021

New 90-day high: NT$31.80

Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?

New 90-day high: NT$25.50

Third quarter 2020 earnings released: EPS NT$0.14

New 90-day low: NT$20.30

New 90-day low: NT$21.00

New 90-day low - NT$22.35

New 90-day low - NT$22.60

First half earnings released

Geschäftsführer

Amtszeit